Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Long-Term Safety of Adalimumab for Children with Ulcerative Colitis Who Completed Previous Study

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Poland Slovakia
  • Study of anakinra safety and effectiveness given by injection under the skin in patients with cystic fibrosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany
  • Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors

    Not recruiting

    3 1 1
    Investigated Drugs:
    Croatia Denmark France Italy Poland Portugal +2
  • Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    Not recruiting

    3 1 1
    Investigated Diseases:
    France Germany Italy Poland
  • Study on the Effects of Ozanimod for Children with Moderate to Severe Crohn’s Disease Not Responding to Usual Treatments

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Hungary Poland Spain
  • Study on the Safety and Effectiveness of Rozanolixizumab in Children with Generalized Myasthenia Gravis

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    Italy Poland
  • Study on the Long-Term Safety of PTC923 (Sepiapterin) for Patients with Phenylketonuria

    Not recruiting

    3 1 1
    Czechia Denmark France Germany Italy The Netherlands +4
  • Study on the Safety and Pharmacokinetics of Risdiplam in Infants with Spinal Muscular Atrophy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Germany Italy The Netherlands Norway Poland
  • Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Poland
  • Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Belgium Czechia Denmark Finland France +7